10 Covid-19 Candidate Vaccines In Clinical Evaluation
BioSpectrum Asia|June 2020
The rapid spread of the novel coronavirus is a reminder of how global populations and economies are interconnected. The pandemic is integrating the global healthcare force by exposing the obvious realities that no single individual, company, or country can solve the pandemic crisis alone. Researchers are optimistically demonstrating best-in-class resources from the lab to manufacturing to advance the innovations at multiple vaccine candidates. Indeed, the global biopharma manufacturing industry is funding and expanding its capabilities for vaccine production on an ‘’at-risk basis’’ to facilitate the world’s immediate need and demand. Novel paradigms of Next-generation vaccine technology platforms are accelerating the development of “one life-saving vaccine” to nullify the repulsive humanitarian and economic impact. According to the WHO, as of May 30 there are 10 vaccines under clinical evaluation which have already progressed to human trials and 121 candidates are in preclinical evaluation.
Hithaishi C Bhaskar
10 Covid-19 Candidate Vaccines In Clinical Evaluation

As COVID-19 continues to ravage the global population, vaccination is becoming the sole hope for an effective disease control and prevention. Numerous pharmaceutical firms are racing and competing to develop a potential vaccine by deploying all their skills and resources. Companies have substantially accelerated the timeframe of vaccine production in comparison to the typical vaccine development process.

The publication of genetic sequence of SARS-CoV-2 on January 11, triggered intense global R&D activity towards vaccine development. Fortunately, up until the virus has not mutated to any significant extent maintaining its relatively stable SARS-CoV-2 genome. Currently, there exist roughly 4 to 10 genetic variations between the origin virus from Wuhan and the strains currently circulating. That’s a relatively small number of mutations for having passed through a large number of people. This makes it advantageous towards researchers attempt to create a single version of the COVID-19 vaccine.

This genomic data paved the way for range of novel technology platforms to evaluate vaccine development landscape for COVID-19, including nucleic acid (DNA and RNA), virus-like particle, peptide, viral vector (replicating and nonreplicating), recombinant protein, live attenuated virus and inactivated virus approaches. Vaccines based on viral vectors offer a high level of protein expression and long-term stability, and induce strong immune responses. Of the confirmed active vaccine candidates, 72 per cent are being developed by private/industry developers, with the remaining 28 per cent of projects being led by academic, public sector and other non-profit organizations.

この記事は BioSpectrum Asia の June 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

この記事は BioSpectrum Asia の June 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

BIOSPECTRUM ASIAのその他の記事すべて表示
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024